Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Palisade Bio, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 28 | 25 | −3 |
| Shares | 1.30M | 879.5K | −423.9K (−32.5%) |
| Value | $1.70M | $930.0K | −$765.0K (−45.1%) |
New holders (2)
Institutions that held Palisade Bio, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 69,842 | $74.0K | 0.00% |
| JPMorgan Chase & Co | 983 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Palisade Bio, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Altium Capital Management LP | 333,954 | $434.0K |
| Sabby Management, LLC | 52,500 | $68.0K |
| Private Advisor Group, LLC | 28,500 | $37.0K |
| Gsa Capital Partners LLP | 10,454 | $14.0K |
| Two Sigma Advisers, LP | 10,500 | $14.0K |